Web Resources

ADDITIONAL HELPFUL INFORMATION

These websites are maintained by third parties. EUSA Pharma is not responsible for the content of these or any other third party sites.

General Cancer and Pain Resources:

Breast Cancer Resources:

Prostate Cancer Resources:

Multiple Myeloma Resources:

Back to previous page

QUADRAMET® causes bone marrow suppression. Before QUADRAMET is administered, consideration should be given to the patient's current clinical and hematologic status and bone marrow response history to treatment with myelotoxic agents. Because of the unknown potential for additive effects on bone marrow, QUADRAMET should not be given concurrently with chemotherapy or external beam radiation therapy unless the clinical benefits outweigh the risks.

Q-0260-07